Oral therapy for rosacea

Journal of Drugs in Dermatology, Jan, 2006 by Hilary E. Baldwin

34. Coxon A, Pallis C. Metronidazole neuropathy. J Neurol Neurosurg Psychiatry. 1976;39:403-405.

35. Wienbren M, Perinpanayagam R, Camba L, et al. Convulsions and encephalopathy in a patient with leukemia after treatment with metronidazole. J Clin Pathol. 1985;38:1076.

36. Nikolowski J, Plewig G. Oral treatment of rosacea with 13-cis-retinoic acid. Hautarzt. 1981;32:575-584.

37. Schmidt J, GebhartW, Raff M, Spona J. 13-cis-retinoic acid in rosacea. Clinical and laboratory findings. Acta Derm Venereol. 1984;64:15-21.

38. Plewig G, Nikolowski J, Wolff H. Action of isotretinoin in acne rosacea and gram-negative folliculitis. J Am Acad Dermatol. 1982;6:766-785.

39. Hoting E, Paul E, Plewig G. Treatment of rosacea with isotretinoin. Int J Dermatol. 1986;25:660-663.

40. Marsden J, Shuster S, Neugebauer M. Response of rosacea to isotretinoin. Clin Exp Dermatol. 1984;9:484-488.

41. Ertl G, Levine N, Kligman A. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994;130:319-324.

42. Erdogan F, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol. 1998;134:884-885.

43. Irvine C, Kumar P, Marks R. Isotretinoin in the treatment of rosacea and rhinophyma. In: Acne and Related Disorders: Proceedings of an International Symposium, eds Marks R, Plewig G. London: Martin Dunitz; 1988:301-305.

44. Krause M, Torricelli R, Kundig T, et al. Dapsone in granulomatous rosacea. Hautarzt. 1997;48:246-8.

45. Spirov G, Berova N, Vassilev D. Effect of oral inhibitors of ovulation in treatment of rosacea and dermatitis perioralis in women. Aust J Dermatol. 1971;12:145-154.

46. Mauss J. Cyproterone therapy of papulopustular rosacea in women. Hautarzt. 1981;32:94-95.

47. Aizawa H, Nimura M. Oral spironolactone therapy in male patients with rosacea. J Dermatol. 1992;19:293-297.

48. Bernstein J, Soltani K. Alcohol-induced rosacea flushing blocked by naloxone. Br J Dermatol. 1982;107:59-61.

49. Wollina U. The response of erythematous rosacea to ondansetron. Br J Dermatol. 1999;140:561-562.

50. Bikowski J. Rosacea: where are we now? J Drugs Dermatol. 2004;3:251-261.

51. Wilkin J. Effect of subdepressor clonidine on flushing reactions in rosacea. Change in malar thermal circulation index during provoked flushing reactions. Arch Dermatol. 1983;119:211-214.

52. Dahl M. Pathogenesis of acne. Adv Dermatol. 2001;17:29-45.

53. Espersen F. Resistance to antibiotics used in dermatological practice. Br J Dermatol. 1998;139:4-8.

54. Cooper A. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Aust. 1998;169:259-261.

55. Ross J, Snelling A. Carnegie E, et al. Antibiotic resistant acne: lessons from Europe. Br J Dermatol. 2003;148:467-478.

56. Eady A, Cove J, Layton A. Is antibiotic resistance in cutaneous Propionibacteria clinically relevant? Implications of resistance for acne patients and prescribers. Am J Clin Dermatol. 2003;12: 813-831.

57. Leyden J, McGinley K, Cavalieri S, et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol. 1983;8:41-45.